• Dimerix receives US$30 million (~AU$48 million) upfront payment from Amicus
• Dimerix eligible for further potential development milestones of up to US$560 million (~AU$892 million) plus tiered royalties on DMX-200 net US sales
• Collectively the license deals provide up to ~AU$1.4 billion in total upfront payments and potential milestone payments, plus royalties on net sales

Dimerix Limited, a biopharmaceutical company with a Phase 3 clinical asset in kidney disease, has announced that it has received the initial payment of US$30 million (AU$48 million) in line with the recently announced license agreement with Amicus Therapeutics. Under the agreement, Amicus has been granted exclusive rights to commercialize DMX-200 for FSGS in the United States. Dimerix now has four high-quality partners across multiple territories, providing strong support for Dimerix in advancing and commercializing DMX-200 as a potential new treatment for FSGS. Collectively across all licenses, Dimerix may become eligible for up to ~AU$1.4 billion in total upfront payments and potential milestone payments, plus royalties on net sales. Under the Amicus agreement, Dimerix may become eligible to receive potential success-based development and regulatory milestone payments of up to US$75 million (~AU$119 million) until FDA approval of DMX-200 in FSGS, US$35 million (~AU$56 million) on first sale, commercial sales milestone payments of up to US$410 million (AU$653 million), and tiered royalties from the low-teens to low-twenties percentages of DMX-200 net sales in the U.S. In addition, Dimerix is eligible to receive up to US$40 million (~AU$64 million) in milestone payments for potential future indications. Dimerix continues to focus on licensing opportunities with potential partners in territories other than those covered by the Amicus, Advanz Pharma, Taiba and FUSO license agreements.

Dimerix may become eligible to receive potential success-based development and regulatory milestone payments of up to US$75 million (~AU$119 million) until FDA approval of DMX-200 in FSGS, US$35 million (~AU$56 million) on first sale, commercial sales milestone payments of up to US$410 million (AU$653 million), and tiered royalties from the low-teens to low-twenties percentages of DMX-200 net sales in the U.S.